论文部分内容阅读
[目的]观察幽门螺杆菌(Hp)感染慢性胃炎患者红细胞膜补体受体1型(CR1)分子表达特点以及治疗对其表达的影响,并探讨其临床价值。[方法]Hp阳性(+)慢性胃炎58例,给予抗Hp三联和胃动力药(得乐冲剂、普瑞博思、阿莫西林和甲硝唑)治疗2周。治疗前及治疗结束后分别进行胃镜及Hp检测,并采用免疫酶联(ELISA)法定量测定CR1分子的数量。[结果]Hp(+)组治疗后有2例胃黏膜无炎症,较治疗前轻度例数显著增高,中、重度例数显著降低(P<0.01)。Hp(+)组治疗前外周血红细胞CR1分子数量显著低于正常对照组(P<0.01),治疗后显著升高(P<0.01)。[结论]Hp感染慢性胃炎患者抗Hp三联和胃动力药联用,不仅能显著改善黏膜炎症表现,还能增加红细胞CR1分子活性,提高红细胞免疫功能。
[Objective] To observe the expression of erythrocyte membrane complement receptor type 1 (CR1) gene in Helicobacter pylori (Hp) infected chronic gastritis patients and the effect of treatment on its expression, and to explore its clinical value. [Method] Fifty - eight Hp positive (+) chronic gastritis patients were treated with anti - Hp triple therapy and gastric motility drug (Delek powder, Puriper, amoxicillin and metronidazole) for 2 weeks. Gastroscopy and Hp detection were performed before treatment and after treatment, and the number of CR1 molecules was quantitatively determined by ELISA. [Results] There was no inflammation in 2 cases of gastric mucosa after Hp (+) treatment, which was significantly higher than that before treatment, and the number of moderate and severe cases was significantly decreased (P <0.01). The number of CR1 in peripheral blood red blood cells in Hp (+) group before treatment was significantly lower than that in normal control group (P <0.01), and significantly increased after treatment (P <0.01). [Conclusion] The combination of anti-Hp triple therapy and gastric motility drug in Hp-infected patients with chronic gastritis can not only significantly improve the mucosal inflammation, but also increase the activity of erythrocyte CR1 and improve the immune function of erythrocytes.